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Abstract
The continuing education course on Developmental Neurotoxicity Testing (DNT) was designed to
communicate current practices for DNT neuropathology, describe promising innovations in
quantitative analysis and noninvasive imaging, and facilitate a discussion among experienced
neuropathologists and regulatory scientists regarding suitable DNT practices. Conventional DNT
neuropathology endpoints are qualitative histopathology and morphometric endpoints of
particularly vulnerable sites (e.g., cerebral, cerebellar, or hippocampal thickness). Novel imaging
and stereology measurements hold promise for automated analysis of factors that cannot be
effectively examined in routinely processed specimens (e.g., cell numbers, fiber tract integrity).
The panel recommended that dedicated DNT neuropathology data sets be acquired on a minimum
of 8 sections (for qualitative assessment) or 3 sections (for quantitative linear and stereological
analyses) using a small battery of stains to examine neurons and myelin. Where guidelines permit
discretion, immersion fixation is acceptable for younger animals (postnatal day 22 or earlier), and
peripheral nerves may be embedded in paraffin. Frequent concerns regarding DNT data sets
include false-negative outcomes due to processing difficulties (e.g., lack of concordance among
sections from different animals) and insensitive analytical endpoints (e.g., qualitative evaluation)
as well as false-positive results arising from overinterpretation or misreading by inexperienced
pathologists.
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The impact of developmental neurotoxicity on individuals, their families, and their
communities is a growing concern around the world. Many factors enhance the vulnerability
of the immature nervous system to xenobiotics. Complex processes for building and
integrating new neural circuits are typically more sensitive to disruption than are the routine
functions required of adult neural cells (Rodier 1994; Claudio et al. 2000). Protective
systems (e.g., blood-brain barrier integrity, detoxifying enzymes) are less developed in
newborns and juveniles. In addition, the developing brain has a neurochemical profile that
increases its susceptibility to anesthetic-induced apoptotic neuronal degeneration (Jevtovic-
Todorovic et al. 2003). Children are also more likely to encounter neurotoxicants (both by
using taste to explore the world and by regular proximity to contaminated ground surfaces;
National Research Council [NRC] 1993) and are less able to neutralize them (due to
impaired elimination and detoxification pathways during prenatal and early postnatal
periods of development; Schwenk et al. 2003). In the past few decades, developmental
neurotoxicity “epidemics” in humans from environmental contaminants (e.g., lead [Winneke
1996], methyl mercury [Castoldi et al. 2008], pesticides [Jurewicz and Hanke 2008]) and
lifestyle-related toxicity(e.g., drugs of abuse [Deraufet al. 2009]and fetal alcohol syndrome
[Bearer 2001]) have increased societal awareness that a more comprehensive regulatory
approach to developmental neurotoxicity testing (DNT) is desirable to protect public health.
The ongoing evolution of nonclinical DNT assessment necessitates periodic reevaluation of
DNT neuropathology practices (Hass 2003; Kaufmann 2003; Bolon et al. 2006; Kaufmann
and Gröters 2006; Bolon et al. forthcoming). A current challenge for DNT neuropathologists
is to move beyond conventional qualitative descriptions of neuroanatomic changes (gross
and/or microscopic) to incorporate more quantitative endpoints. The dilemma posed by the
shift toward more quantifiable analysis stems from the conflict between the benefits (greater
objectivity, less bias) and disadvantages (labor intensiveness, slowness) afforded by
historically available quantitative techniques. Several recent technological innovations in
quantitative neuroanatomy may engender modifications in the traditional DNT
neuropathology battery in the future.
The continuing education course on DNT held at the 2010 joint scientific symposium of the
Society of Toxicologic Pathology (STP) and the International Federation of Societies of
Toxicologic Pathologists (IFSTP) was created with three objectives in mind. The first was to
review current “best practices” for DNT neuropathology analysis. The second goal was to
describe new advances in neural stereology and noninvasive neural imaging that promise to
increase the efficiency and speed with which high-quality quantitative data may be acquired.
The third aim was to consider the essential elements necessary to instill confidence that a
regulatory review based on DNT neuropathology data is well founded. The first two ends
were addressed in a series of four technical talks, while the last purpose was accomplished
via a panel discussion.
Current and Potential Components of the DNT Neuropathology Analysis
The first talk by Dr. Wolfgang Kaufmann provided an “Overview of the Role of
Neuropathology and Morphometrics in DNT Assessment.” At present, the neuropathology
analysis for a typical DNT study emphasizes qualitative histopathologic scoring in
conjunction with a small battery of straightforward quantitative measurements (usually total
or region-specific brain weights as well as two-dimensional [2D] areal or linear
morphometric measurements) for such sensitive brain regions as the cerebral cortex,
cerebellum, and hippocampus (U.S. Environmental Protection Agency [EPA] 1998; Bolon
et al. 2006; Kaufmann and Gröters 2006; Organisation for Economic Cooperation and
Development [OECD] 2007). Both the qualitative and quantitative evaluations are
commonly complicated by the difficulty in reliably obtaining comparable sections through
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the same brain structures from all subjects. This problem may be dealt with by using tools
(e.g., brain molds) to produce tissue blocks with equivalent orientations but is most
commonly solved by cutting multiple serial or step sections to ensure that structures are
oriented equivalently for all animals. The conventional DNT approach reliably detects large-
scale defects in brain size (e.g., altered weight) and structure (e.g., anatomic disorganization,
cellular ectopia) but is less able to distinguish alterations in cell number and tissue volume;
even experienced neuropathologists cannot discern subtle deficits in cell number (<25% to
30%). Two additional disadvantages are that conventional DNT neuropathology endpoints
provide a limited survey of microscopic changes in 2D for a modest number of brain regions
and are acquired only at necropsy, which may preclude recognition of early transient
abnormalities that arise immediately after initial toxicant exposure. The three remaining
technical talks presented updates on recent developments in DNT neuropathology that
promise to help address such challenges.
The second lecture, delivered by Professor Hans Jørgen Gundersen, conveyed “New
Developments in the Application of Stereology to DNT Assessment” for unbiased
evaluation of object distribution, orientation, shape, and size. A decision to include three-
dimensional (3D) stereological analysis in the DNT neuropathology evaluation is typically
made retrospectively using a weight-of-evidence approach or prospectively using historical
information regarding toxicity of the test compound or structurally related molecules.
Although highly sensitive and precise, prior stereological methods and the equipment
available to undertake them have been too cumbersome and time-consuming to implement
on a routine basis during DNT. However, new advances in stereological theory, sampling
protocols, automated software, and imaging devices have greatly improved the efficiency
and speed with which such data may be acquired (Korbo et al. 1990; Madeira et al. 1995;
Dorph-Petersen, Nyengaard, and Gundersen 2001). The preferred stereological approaches
for DNT neuropathology are likely to be Cavalieri-based volume estimates and optical or
physical disector-based neuron counts of selected brain regions (e.g., cerebral cortex,
cerebellum, corpus callosum, corpus striatum [basal ganglia], diencephalon [thalamus and
hypothalamus], hippocampus, and mesencephalon). Adequate precision is typically achieved
by evaluating 25 to 50 fields in 6 to 8 serial, 3-mm-thick disectors (where a disector consists
of two adjacent sections) to acquire about 100 object counts. This disector method is fairly
rapid: approximately 4 hrs to serially section a rat brain in the sagittal plane, and 1 hr per site
for each animal to perform systematic uniform random sampling at 400x. The discriminative
strength of quantitative DNT neuropathology endpoints (brain weight → 2D linear
morphometry → 3D stereology), and thus the probability for pinpointing the extent and
location of developmental brain lesions, increases as one moves from gross to a more
detailed and quantitative analysis (de Groot et al. 2005).
The third talk by Dr. Al Johnson described “Magnetic Resonance Microscopy(MRM) of the
Developing Brain,” while the final talk by Dr. Kathleen Sulik discussed the “Application of
MRM to Defining Toxicant-Induced Abnormalities in the Developing Brain.” The MRM
approach and its variants, such as diffusion tensor imaging (DTI), are noninvasive means for
the in vivo or ex vivo examination of structural changes in the immature brain (Lester et al.
2000; Huang et al. 2008; Lodygensky et al. 2009). Currently available MRM instruments
acquire digital 2D “sections” through the entire brain at a sufficient resolution (typically 20
mm [Petiet et al. 2008] to 100 mm [Johnson et al. 2006], acquired in approximately 45 min
per sample) to permit evaluation comparable to microscopic analysis at magnifications up to
100x (10x objective). Automated algorithms allow assembly of the 2D serial sections into
3D reconstructions that highlight the site and extent (linear or volumetric involvement;
Parnell et al. 2009; Godin et al. 2010) of structural disruption in the brain. Processing
conditions may be modified to optimize MRM data (Petiet, Hedlund, and Johnson 2007).
Discrete neural domains may be highlighted in the 3D reconstructions to facilitate structural
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comparison (qualitative and quantitative; Johnson et al. 2006) between normal and toxicant-
exposed conceptuses. Complete fiber tracts may even be followed as they course between
brain regions, permitting qualitative and quantitative assessment of toxicant-induced
disruption in structural development. This approach is a powerful tool for investigating the
potential pathogenesis of developmental neurotoxicity.
Regulatory Experience with DNT Neuropathology Analysis
The discussion regarding “A Regulatory Perspective on New Developments in
Morphometric Approaches to Developmental Neurotoxicity Assessment” included
experienced DNT neuropathologists (Drs. Robert Garman, Georg Krinke, and Peter Little)
and regulatory scientists (Susan Makris and Dr. Daniel Mellon) as panelists, with regulatory
scientist Dr. Karl Jensen as moderator. The objective was to identify common themes that
arise in the course of DNT neuropathology evaluations and, where necessary, to define
potential approaches for addressing such issues.
One outcome recognized by the panel was that not all DNT neuropathology measurements
are created equal. This conclusion is supported by a recent retrospective examination of data
from 69 guideline DNT studies of acceptable quality that were submitted to the EPA Office
of Pesticide Programs (EPA-OPP). At the lowest observed adverse effect level (LOAEL),
linear morphometry of tissue sections was found to be a more sensitive index of structural
damage to the immature nervous system than either brain weight measurements or
qualitative histopathology scores, and can be as or more sensitive than behavioral data
(Raffaele et al. 2010). In like manner, gross linear measurements of the untrimmed brain
may detect significant treatment-related differences when linear morphometric analysis at
the microscopic level was inconclusive due to the imprecise positioning of the
“homologous” tissue sections (Senn et al. 2010).
A second conclusion discussed by the panel was that the application of “novel” stereological
and imaging methods to DNT neuropathology analysis will require a considerable degree of
additional validation before these approaches may be considered for routine implementation
in a regulatory setting. Particular care will be needed to ensure that the predictivity,
reliability, reproducibility, and sensitivity of nonclinical DNT models are applicable to
human developmental neurotoxicity disorders. Extensive comparison between new methods
and currently recognized standards (e.g., 3D stereology vs. 2D linear morphometry, high-
resolution MRM vs. conventional histopathology of tissue sections) using a battery of
known developmental neurotoxicants will be required to substantiate the utility of the new
techniques. A further consideration that must be addressed for these innovative approaches
is to ascertain whether the presumably greater statistical sensitivity at the low end of the
dose-response curve is actually predictive of a biologically relevant adverse outcome.
Finally, the collective experiences of the panel members indicated that a spectrum of DNT
neuropathology practices may be acceptable, depending on the specifications that are given
in various DNT guidelines (EPA 1998; OECD 2007).
• The panel held that the neuropathology component of dedicated DNT studies
should routinely incorporate certain practices:
– A minimum set of 6 (and ideally 8) coronal sections to show major brain
regions (especially such sensitive sites as the cerebral cortex,
hippocampus, and cerebellum). However, some neuropathologists
recommend evaluating 1 or more parasagittal (longitudinal) sections near
the mid-line (to better visualize the major fiber tracts connecting major
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brain centers) in conjunction with 4 to 6 coronal hemi-sections (which will
permit evaluation using traditional brain landmarks).
– A minimal staining battery of hematoxylin and eosin (to assess general
brain architecture) and Luxol fast blue (to evaluate myelin). Fluoro-Jade B
or a silver degeneration method (to demonstrate dying neurons) are not
typically employed for DNT neuropathology because early neuronal injury
(e.g., apoptosis) is unlikely to be detected at the end of the exposure
period. Immunohistochemical detection of glial fibrillary acidic protein
(GFAP) may be used to reveal enhanced glial production at sites of
damage, but this method is more discriminating in young adult animals
(postnatal day [PND] 60–70) rather than juveniles (PND 11 or PND 21–
22).
• The panel felt that, where permitted by guidelines, DNT neuropathologists should
have discretion to select among various practices:
– The preferred time for early DNT assessment is PND 21–22 as neural
tissues exhibit less structural variation and are less fragile relative to PND
11.
– Perfusion fixation is required for proper brain fixation at PND 60–70, but
immersion fixation is an acceptable means of preservation at PND 11 and
PND 21–22 due to the difficulty in reliably perfusing such small animals.
– The structure of peripheral nerves can be reliably evaluated in samples
embedded in paraffin.
• What kinds of background alterations are commonly reported in immature rodent
(mouse and rat) brains, and how often do they occur? The most frequent findings
are visible differences in brain size (evident at PND 11; Garman et al. 2001) and
increased numbers of displaced neurons (heterotopia), which can occur in
laminated regions at multiple sites.
• What kinds of positive control procedures are recommended (i.e., concurrent vs.
historical), and what DNT aspect are they validating (the sensitivity of the test
species, the sensitivity of the quantitative method, and/or the proficiency of the
pathologist)? The panel felt that concurrent controls are necessary for confirming
the existence of positive findings within a study but that historical data using a
positive control agent serves as evidence that a particular institution and its
personnel can reliably perform a DNT study. The panel recommends that a positive
control agent be included from time to time in future studies to validate that new
personnel and novel techniques can reliably discriminate toxicant-induced changes;
however, a specific time frame for repeating the positive control group was not
stated by the discussants. The intermittent addition of positive control groups also
confirms the ongoing sensitivity of the test species.
Data sets to support the range of acceptable practices defined above using the experiences of
the panel members have yet to be fully reported in the literature.
The panel felt that major concerns with DNT neuropathology data sets usually stem from
inaccurate (false-negative or false-positive) conclusions rather than from analysis of
insufficient tissues. False-negative outcomes arise from processing difficulties (e.g., lack of
concordance among sections from different animals) and/or insensitive analytical endpoints
(e.g., qualitative evaluation). False-positive results usually signify overinterpretation or
misreading of background findings or artifacts by inexperienced pathologists. The panel felt
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that reports should detail exactly what brain structures were examined (e.g., cerebellum,
deep cerebellar nuclei, pons) rather than using broad nonspecific terms (e.g., hindbrain).
The panel was impressed with the potential for noninvasive neural imaging to substantially
improve the neuropathology evaluation of DNT studies in the future. The current state of the
art does not permit high-resolution, longitudinal (i.e., time course) neural imaging studies of
the brain in vivo because living tissues move during breathing and cardiac contractions.
However, a welcome advantage once the technology matures will be the ability to obtain
qualitative and quantitative DNT neuropathology data at multiple time points from one
animal.
The panel consensus was that better standardization of DNT neuropathology analyses
among sponsors and across regulatory agencies and geographic regions should be a primary
goal in any future revision of DNT guidelines. The discussants felt that such harmonization
in the near term would provide meaningful improvement in current efforts to assess the risk
of developmental neurotoxicity. Regular inclusion of innovative stereological and imaging
methods in the DNT process will likely be warranted in the future. However, given the
newness of these novel technologies, the discussants could not suggest a timetable or any
criteria for deciding when the time will have arrived to request routine inclusion of such data
in product registration packages.
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